A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: usually (759), normally (347), commonly (128)

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description
Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple Myeloma – Bortezomib (IV)-Dexamethasone-Panobinostat-Thal
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

Everolimus-Lenvatinib

Description
Chemotherapy Protocol RENAL CELL EVEROLIMUS and LENVATINIB Regimen • Renal Cell – Everolimus-Lenvatinib Indication • Confirmed histological
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Everolimus-Lenvatinib.pdf

Bendamustine-Rituximab

Description
Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-RITUXIMAB There are multiple versions of this protocol in use. Please ensure you have the correct protocol for the relevant diagno
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Rituximab.pdf

Bendamustine-Polatuzumab-Rituximab

Description
Chemotherapy Protocol LYMPHOMA BENDAMUSTINE-POLATUZUMAB-RITUXIMAB Regimen • Lymphoma – Bendamustine-Polatuzumab-Rituximab Indication • Histologically diagnosed diffuse large B cell
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Polatuzumab-Rituximab.pdf

Bendamustine-Obinutuzumab

Description
Chemotherapy Protocol Non-Hodgkin Lymphoma Bendamustine-Obinutuzumab Regimen • NHL – Bendamustine-Obinutuzumab Indication • Obinutuzumab in combination with bendamustine followed by
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Obinutuzumab.pdf

Audit and Risk Committee ToR Jan 2022

Description
Audit and Risk Committee Terms of Reference Date Issued: 27 January 2022 Review Date: January 2023 Document Type: Committee Terms of Referen
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2022.pdf

MyelomaVTDBortezomib(SC)DexamethasoneThalidomideVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD (SC-28)-BORTEZOMIB (SC)-DEXAMETHASONE-THALIDOMIDE (28 day) Regimen Multiple Myeloma – VTD (28)-Bortezomib (SC)-Dexamethasone-Thalidomide
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVTDBortezomibSCDexamethasoneThalidomideVer1.pdf

MyelomaVTDBortezomib(IV)DexamethasoneThalidomideVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA VTD (IV-28)-BORTEZOMIB (IV)-DEXAMETHASONE-THALIDOMIDE (28 day) Regimen Multiple Myeloma – VTD (IV-28)-Bortezomib (IV)-Dexamethasone-Thalidom
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaVTDBortezomibIVDexamethasoneThalidomideVer1.pdf

MyelomaRCDCyclophosphamideDexamethasoneLenalidomidel(RCD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA RCD-CYCLOPHOSPHAMIDE-DEXAMETHASONE-LENALIDOMIDE There are multiple versions
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaRCDCyclophosphamideDexamethasoneLenalidomidelRCDVer1.pdf

MyelomaMPTMelphalan(PO)PrednisoloneThalidomideVer1

Description
Chemotherapy Protocol MULTIPLE MYELOMA MPT-MELPHALAN (PO)-PREDNISOLONE-THALIDOMIDE Regimen Multiple Myeloma – MPT-Melphalan (PO)-Prednisolone-Thalidomide Indication First line tre
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPTMelphalanPOPrednisoloneThalidomideVer1.pdf
161 to 170 of 218
Previous … 15 16 17 18 19 … Next